Phoenix Life Sciences International Announces Michael Gobel as Finance Advisor

DENVER, CO – February 27, 2019 – Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that Michael Gobel has joined as the company’s Board of Directors to help the company navigate the next steps for larger capital investment and compliance for a planned uplisting to NASDAQ.

“Financial management and a strong capitalized organization both play large roles in the progression of our international expansion,” said Phoenix Life Sciences International CEO Martin Tindall. “Michael Gobel’s extensive experience in risk assessment, financial guidance and balancing various capital opportunities will be imperative in implementing a successful long-term financial strategy.”

Gobel holds a Master’s degree in Applied Finance from Macquarie University in Sydney and has more than three decades of experience in the finance industry. He serves as Company Director and Portfolio Manager, managing investments and associated risk in local and overseas equity markets. Additionally, Gobel currently serves as a consultant on economic developments and major projects while also representing a variety of interests to federal ministers and senior government advisors. Michael is on a number of Boards including as Deputy Chairman of an Australian Bank, assisting in guiding the company’s corporate governance and strategy, ensuring best practices and encouraging a culture of proactive risk management.

“Assessing and choosing financial decisions and managing reducing risk factors will help ensure that Phoenix Life achieves forward progression in company milestones and continual success,” said Phoenix Life’s new Board Member, Michael Gobel. “I look forward to working with a company that has many innovative and potentially revolutionary goals.”

To learn more about Phoenix Life Sciences International, please visit

About Phoenix Life Sciences International Limited
Phoenix Life Sciences International Limited is an adaptive healthcare solutions company. Our business is to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. We strive to create partnerships and integrate these programs for human health into communities worldwide as part of our Global Health Initiative.

Information contained in this press release regarding Phoenix Life Sciences International, Limited and its subsidiaries, (the “Companies”) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.

These statements have not been evaluated by the FDA and therefore the products sold by Phoenix Life Sciences International Limited are not available on U.S.

Phoenix Life Sciences International Limited does not sell or distribute any products in the United States that are in violation of the United States Controlled Substances Act (US.CSA). The Company does not grow, sell, or distribute cannabis-based products in the United States and is solely involved with the legal distribution of pharmaceutical products that contain active ingredients derived from the cannabis plant within international markets.

Investor Contact:
Phone: 1.888.717.5655 or international +1.720.699.7222

Media Contact:
Kathryn Reinhardt
CMW Media

Leave a Reply

Sign up for our newsletter

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact